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generally slower than that of the comparator group, i.e. 1.21±
0.21 vs. 1.31± 0.23 m/s (p= 0.017). Despite diminished walking
speed, the external knee AddM was significantly higher in the
OA group than in the comparator group (2.9±0.7 vs. 2.2±0.7;
p<.001), while the hip AddM was reduced (3.9±0.8 vs. 4.3 ±0.9,
p=0.02). After completion of the strengthening program, the
self-selected normal speed of the four pilot patients increased
by 5.6% compared to the initial base values. In addition, the
external the knee AddM decreased by 3.6%, while the hip AddM
increased by 9.6%.
Conclusions: In accordance with previous observations, these
data suggest that in mild knee OA, the increased loading at
the knee is accompanied by decreased loading at the hip. The
chronically reduced recruitment of hip abductors stabilizing the
external hip AddM may result in hip muscle weakness over time,
and thus cause an unstable pelvis during gait yielding higher
medial loads at the knee. In our pilot patients, a focused hip
muscle strengthening program favorably altered both hip and
knee joint moments in subjects with knee OA, likely through
postural adaptations at the trunk and pelvis during gait. This
initial work suggests that focused muscle strengthening may
be a promising intervention for reducing medial compartment
loading patterns in subjects with knee OA.
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Purpose: Loss of meniscus tissue frequently leads to decreased
clinical function and activity levels. However, no report has quan-
tified the amount of meniscus tissue removed at meniscectomy
and correlated the meniscus tissue loss with clinical symptoms,
function, and activity. The purpose of this study was to determine,
prospectively, the amount of tissue loss at time of partial medial
meniscectomy and then correlate extent of meniscus loss with
clinical symptoms, function, and activity levels 2 years following
the index meniscectomy.
Methods: In a randomized controlled investigational device clin-
ical trial (Level of Evidence I), 149 patients 18 to 60 years old
underwent partial medial meniscectomy and served as controls.
There were 81 acute (no prior meniscus surgery) and 68 chronic
(1 to 3 prior partial meniscectomies on the involved meniscus)
patients. At index surgery, size of the meniscus defect was
measured using specially designed instruments, and percent of
meniscus loss was calculated based on actual measurements.
Patients were followed clinically for a minimum of 2 years follow-
ing meniscectomy. At each follow-up, every patient completed
questionnaires including Lysholm and Tegner scores to assess
function and activity. Amount of meniscus tissue at index surgery
was correlated with the individual domains of the Lysholm scale.
Tegner index was calculated to determine the amount of lost
activity regained 2 years after surgical intervention.
Results: Two-year data were available for 127 patients
(85% follow-up). There was a significant correlation between
the amount of meniscus tissue remaining following the in-
dex meniscectomy and 2-year Lysholm domains of squat-
ting (r=0.281, p=0.001), stair-climbing (r=0.251, p=0.004), and
swelling (r=0.261, p=0.003). In particular, it is noteworthy that
patients who had >50% of their meniscus remaining had sig-
nificantly better function than patients who had <50% menis-
cus remaining. Patients who had worse or no improvement in
pain symptoms at 2 years averaged 42% meniscus remaining,
while patients who had improved pain scores had on average
51% meniscus remaining. Tegner index for patients with <50%
meniscus remaining averaged 24%, and for patients with >50%
meniscus remaining averaged 52% (p=0.017); hence, a greater
amount of meniscus tissue remaining allowed patients to regain
significantly more of their lost activity.
Conclusions: There is a significant correlation between the
amount of meniscus tissue removed at meniscectomy and symp-
toms, function, and activity 2 years after surgery. This study con-
firms the importance of preserving as much meniscus tissue as
possible at the time of meniscus repair or meniscectomy as well
as the potential positive benefits of regrowing or replacing lost
meniscus tissue in order to minimize clinical symptoms that may
be suggestive of early degenerative changes.
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Purpose: RN624 is a humanized IgG2 monoclonal antibody
against human nerve growth factor (NGF). NGF is elevated in
conditions of acute and chronic pain and facilitates the impulse
flow in sensory neurons. RN624 has been effective in animal
pain models including arthritis pain, cancer pain and incision
pain. The objective of the first in human clinical study, Protocol
RN624-CL001, was to evaluate the safety and activity of a single
intravenous dose of RN624 in subjects with pain due to knee
OA.
Methods: 121 subjects with knee OA and a knee pain of ≥25
(VAS 0-100) were enrolled in a phase 1 double blinded, random-
ized, placebo controlled trial. The study was conducted in two
parts; a dose escalation (Part 1) followed by a parallel arm (Part
2). 42 subjects (12 placebo, 30 active) were enrolled in 5 dose
escalation cohorts to receive 3, 10, 30, 100, 300, and 1000 μg/kg
RN624 or placebo with 28 days inter-cohort intervals. Once the
safety of RN624 was established in Part 1, 79 subjects were en-
rolled in Part 2 and received either 100 or 300 μg/kg RN624 or
placebo in parallel (N = 27, 26 and 26 respectively). All subjects
received a single infusion of RN624 and were followed for up
to 180 days. Subjects recorded pain scores (VAS 0-100) for the
index knee 4 times a day and walking pain once a day or 28
days in the 3, 10, 30 μg/kg doses and up to 180 days in higher
dose groups. The WOMAC scale was administered during office
visits.
Results: Significant reduction in overall knee pain and walking
pain was observed in doses of 10 μg/kg RN624 and higher
of RN624. The peak effect was achieved by week 4 and was
sustained up to 12 weeks in 100 μg/kg and higher. More than
50% of subjects in 100 μg/kg or higher groups (N=71) experi-
enced at least a 50% reduction in walking pain over 12 weeks
compared to 25% in their placebo counterparts (N=32). A subset
of subjects in 100 μg/kg or higher displayed a transient reduced
efficacy in the 2nd and 3rd weeks; they experienced pain reduc-
tion during the 1st week, decreased pain reduction during the 2nd
and 3rd weeks, and sustained pain reduction up to 12 weeks.
Approximately 55% of subjects who received a single infusion of
100 μg/kg RN624 or higher achieved at least 50% improvement
in WOMAC function and stiffness subscales over 12 weeks post
infusion.
Approximately 25% of RN624 subjects reported adverse events
of altered or abnormal sensation of pain such as dysesthesia,
parasthesia, hyperesthesia, and allodynia. None of these events
were reported in the 3, 10, or 30 μg/kg RN624 groups (N=12).
These events were generally mild to moderate in severity and
transient. They mostly emerged during the first 2 weeks and
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resolved by week 4. No clinically significant abnormalities on
neurological exam, ECG, cognitive testing (HVLT-R) and postural
vital signs were noted.
Conclusions: A single infusion of RN624 reduced pain in sub-
jects with OA of the knee. The peak effect on pain reduction
was observed at approximately 4 weeks post infusion and sus-
tained for 8 weeks thereafter. The reduction in pain was more
pronounced in walking pain. RN624 improved the subject’s func-
tional status including reduced pain while walking, improved
functional activities, and less stiffness (WOMAC subscales). A
trend of dose response in pain reduction was observed among
the lower dose cohorts 3, 10, 30, 100 μg/kg RN624 and the
maximum effect was observed in the 100 μg/kg RN624 group.
The abnormal pain-related adverse events observed appear to
be dose related. The onset and resolution occurred during the
first 4 weeks before the peak effect. The timing of the adverse
events coincided with the reduced efficacy seen transiently in
higher dose groups.
RN624, with well-defined pain relief and tolerability profiles, has
the potential to be useful in the management of chronic pain due
to OA.
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Purpose: The 110kd fibronectin-fragment (FN-f) has been found
to stimulate chondrocyte MMP-13 expression through the activa-
tion of an α5β1 integrin cell-signaling pathway. We have recently
shown that reactive oxygen species (ROS) are required sec-
ondary messengers in the activation of key components of this
pathway including PYK-2, MAP kinases, c-Jun, and NFkB. Ox-
idation of specific cysteine residues, resulting in the formation
of protein sulfenic acids, is a key step in several redox-sensitive
signaling pathways but has not been investigated in integrin path-
ways or in chondrocyte signaling. The objective of the present
study was to utilize a proteomics approach to determine key
redox proteins regulated by sulfenic acid formation in α5β1 sig-
naling that results in chondrocyte MMP-13 expression.
Methods: Human articular chondrocytes, isolated from nor-
mal ankle cartilage, were stimulated in serum-free media with
25μg/ml of the 110kD FN-f in the presence and absence of dime-
done, a reagent which reacts specifically with protein sulfenic
acids. The requirement for sulfenic acid formation in FN-f me-
diated integrin signaling was determined by pre-treating cells
with dimedone (0, 1, 5, 10, 20mM) for 30 mins followed by FN-f
stimulation. Activation of PYK2, MAP kinases, Akt, c-Jun and
NF-κB was measured by immunoblotting cell lysates, prepared
5-45 mins after FN-f stimulation, with phosphorylation-specific
antibodies while MMP-13 production was measured in the con-
ditioned media from cultures treated overnight. Cell survival was
analyzed by staining with calcein and ethidium bromide. Detec-
tion of sulfenic acid-containing proteins formed in response to
FN-f stimulation was performed by adding 5mM of a biotinylated
dimedone analogue (DCP-biotin) to the cell lysis buffer after
FN-f stimulation (rather than pre-treating with dimedone). Un-
stimulated controls were also treated with DCP-biotin in a similar
fashion. Labeled proteins were then pulled down with streptavidin
beads and analyzed on 1-D and 2-D gels.
Results: Pre-treatment with dimedone significantly inhibited FN-
f-stimulated MMP-13 production in a dose dependent manner
with maximal inhibition at 20mM with no reduction in cell sur-
vival at this dose. The inhibition of MMP-13 production was
associated with inhibition of phosphorylation of PYK2 and the
MAP kinases ERK, JNK, and p38 as well as c-Jun and the p65
subunit of NFκB. Of these, the JNK-2 isoform appeared to be
most sensitive with inhibition noted at 5mM dimedone while the
others required 10-20mM. Unlike the others, phosphorylation of
Akt, which is required for anabolic rather than catabolic signal-
ing, was increased with 20mM dimedone pre-treatment. When
DCP-biotin was added after FN-f stimulation, at least 5 proteins
containing sulfenic acid were noted that were uniquely labeled
in FN-f stimulated samples compared to controls. One of these
was identified as JNK-2. Sulfenic acid formation in JNK-2 was
confirmed in chondrocytes transfected with a Flag-tagged JNK-2
expression construct.
Conclusions: These results are the first to show that generation
of protein sulfenic acids is required for the FN-f stimulated inte-
grin signaling which mediates MMP-13 production. JNK-2 was
identified as a key redox-sensitive signaling intermediate but oth-
ers upstream of PYK2 are also likely involved. The specific Cys
residue modified to Cys sulfenic acid in JNK-2 is currently being
identified. Defining the redox sensitive secondary messengers
that regulate MMP-13 expression should aid in the develop-
ment of novel therapeutic targets capable of reducing cartilage
destruction in arthritis.
A52
A NOVEL ACTIVATOR OF MMPS IN CARTILAGE
C. Little, M. Jackson, M. Smith, C. Jackson
University of Sydney, St Leonards, Australia
Purpose: Degradation of articular cartilage characterised by pro-
teolysis of aggrecan and the type II collagen network is a central
feature of osteoarthritis (OA). Significant collagenolysis by matrix
metalloproteinases (MMPs) may signify the point of irreversible
cartilage damage. Numerous catabolic agents upregulate chon-
drocyte synthesis of MMPs, but the mechanism whereby these
enzymes are activated is unclear. Increased levels of Activated
Protein C (APC), an anticoagulant serine protease, are found in
OA. APC is generated through the action of thrombin bound to
thrombomodulin (TM) cleaving protein C (PC) bound to a its cell
surface receptor (EPCR). APC is known to activate MMP-2 but its
potential role in cartilage degradation has not been investigated.
Methods: Ovine articular cartilage was cultured ± 10ng/ml IL-1,
100ng/ml TNF-alpha or 10-6M retinoic acid (RA) ± 2-20 μg/ml
APC ± a broad spectrum MMP inhibitor (marimastat, 300nM) for
4 days. In some experiments cartilage was cultured with APC for
24-96 hours, washed and then incubated with IL-1 or RA. The
release of sulfated glycosaminoglycan (GAG) and hydroxyproline
(HyPro) was compared using ANOVA and Student-Newman-
Keuls post-hoc analysis. MMP-2 and -9 activity in media was
examined by gelatin zymography, and MMP-13 activity measured
with a fluorogenic substrate. In replicate cultures, RNA was
extracted from cartilage and expression of ADAMTS-1, -4 &-5;
MMP-1, -2, -3, -9, -13 &-14; TIMPs 1-4; and PC, EPCR and
TM were evaluated using RT-PCR. PC was immunolocalised
in osteochondral sections of developing human joints and in
cartilage from normal and OA human cartilage.
Results: IL-1, TNF and RA significantly increased cartilage
GAG release (40-60% of total) but did not induce collagen
breakdown over 4 days of culture. APC alone (2-20μg/ml)
had no effect on GAG or collagen release, however, it sig-
nificantly augmented GAG loss from IL-1 and TNF (>80% of
total) but not RA stimulated cultures. In IL-1 and TNF but not
RA stimulated cultures, APC caused substantial collagen (4-
15% of total) loss over 4 days. MMP inhibition abrogated the
APC-augmented GAG and collagen release. Pre-culture with
APC prior to washing and subsequent cytokine stimulation, in-
